Response to Seasonal and Pandemic Influenza: How Can We Win the “War”?

WANG Dayan1 ZHU Wenfei1 CHEN Yongkun2 SHU Yuelong1,2

(1.World Health Organization Global Influenza Collaboration Centre for Reference and Research on Influenza, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China 102206)
(2.School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, China 510275)
【Novelty】As we commemorate 100 years since the 1918 Spanish flu pandemic, much progress has been made, including the research on influenza epidemiology, virology, vaccines, antiviral drugs, and so on; Influenza surveillance and the universal vaccines development should be urgently enhanced for better preparedness and response against influenza pandemic in the future.

【Abstract】As we commemorate 100 years since the 1918 “Spanish flu” pandemic, much progress has been made, including the research on influenza epidemiology, virology, vaccines, antiviral drugs, and so on. However, the influenza surveillance and the universal vaccines development should be urgently enhanced for better preparedness and response against pandemic influenza in the future.

【Keywords】 “Spanish flu” pandemic; Influenza surveillance; Universal vaccine; Influenza virus;

【Funds】 Special Emergency Fund for Ministry of Science and Technology (Project No.10600100000015001206), Title: H7N9)

Download this article


    [1] Johnson N P, Mueller J. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic [J]. Bull Hist Med, 2002, 76 (1): 105–115.

    [2] Shope R E. Swine influenza III. Filtration experiments and etiology [J]. J Exp Med, 1931, 54: 373–385.

    [3] Shope R E. The effect of hemophilus influenzae suis vaccines on swine influenza [J]. J Exp Med, 1937, 66 (2): 169–175.

    [4] Hayden F G. Antivirals for influenza: historical perspectives and lessons learned [J]. Antiviral Res, 2006, 71 (2–3): 372–378.

    [5] Hay A J, Wolstenholme A J, Skehel J J, Smith M H. The molecular basis of the specific anti-influenza action of amantadine [J]. EMBO J, 1985, 4 (11): 3021–3024.

    [6] Von Itzstein M, Wu W Y, Kok G B, Pegg M S, Dyason J C, Jin B, Van Phan T, Smythe M L, White H F, Oliver S W, Colman P M, Varghese J N, Ryan D M, Woods J M, Bethell R C, Hotham V J, Cameron J M, Penn C R. Rational design of potent sialidase-based inhibitors of influenza virus replication [J]. Nature, 1993, 363 (6428): 418–423.

    [7] Yamashita M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza [J]. Antivir Chem Chemother, 2010, 21 (2): 71–84.

    [8] Babu Y S, Chand P, Bantia S, Kotian P, Dehghani A, El-Kattan Y, Lin T H, Hutchison T L, Elliott A J, Parker C D, Ananth S L, Horn L L, Laver G W, Montgomery J A. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design [J]. J Med Chem, 2000, 43 (19): 3482–3486.

    [9] Centers for Disease C, Prevention. Isolation of avian influenza A (H5N1) viruses from humans—Hong Kong, May-December 1997 [J]. MMWR Morb Mortal Wkly Rep, 1997, 46 (50): 1204–1207.

    [10] Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Zhang Y, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y. Human infection with a novel avian-origin influenza A (H7N9) virus [J]. N Engl J Med, 2013, 368 (20): 1888–1897.

    [11] Hause B M, Ducatez M, Collin E A, Ran Z, Liu R, Sheng Z, Armien A, Kaplan B, Chakravarty S, Hoppe A D, Webby R J, Simonson R R, Li F. Isolation of a novel swine influenza virus from Oklahoma in 2011which is distantly related to human influenza C viruses [J/OL]. PLoS Pathog, 2013, 9 (2): e1003176.

    [12] Anonymous. Palese P, Shaw M L. Orthomyxoviridae:The viruses and their replication. In:Knipe DM, Howley PM, editors. Fields Virology, Fifth Edition. Philadelphia:Lippincott Williams & Wilkins [M]. 2007: 1647–1690.

    [13] Fouchier R A, Munster V, Wallensten A, Bestebroer T M, Herfst S, Smith D, Rimmelzwaan G F, Olsen B, Osterhaus A D. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls [J]. J Virol, 2005, 79 (5): 2814–2822.

    [14] Webster R G, Bean W J, Gorman O T, Chambers T M, Kawaoka Y. Evolution and ecology of influenza A viruses [J]. Microbiol Rev, 1992, 56 (1): 152–179.

    [15] Cheung T K, Poon L L. Biology of influenza a virus [J]. Ann N Y Acad Sci, 2007, 1102:1–25.

    [16] Tong S, Li Y, Rivailler P, Conrardy C, Castillo D A, Chen L M, Recuenco S, Ellison J A, Davis C T, York I A, Turmelle A S, Moran D, Rogers S, Shi M, Tao Y, Weil M R, Tang K, Rowe L A, Sammons S, Xu X, Frace M, Lindblade K A, Cox N J, Anderson L J, Rupprecht C E, Donis R O. A distinct lineage of influenza A virus from bats [J]. Proc Natl Acad Sci U S A, 2012, 109 (11): 4269–4274.

    [17] Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M, Yang H, Chen X, Recuenco S, Gomez J, Chen L M, Johnson A, Tao Y, Dreyfus C, Yu W, McBride R, Carney P J, Gilbert A T, Chang J, Guo Z, Davis C T, Paulson J C, Stevens J, Rupprecht C E, Holmes E C, Wilson I A, Donis R O. New world bats harbor diverse influenza A viruses [J/OL]. PLoS Pathog, 2013, 9 (10): e1003657.

    [18] Brown I H. The epidemiology and evolution of influenza viruses in pigs [J]. Vet Microbiol, 2000, 74 (1–2): 29–46.

    [19] Alexander D J. Ecological aspects of influenza A viruses in animals and their relationship to human influenza:a review [J]. J R Soc Med, 1982, 75 (10): 799–811.

    [20] Paules C, Subbarao K. Influenza [J]. Lancet, 2017, 390 (10095): 697–708.

    [21] Paules C I, Sullivan S G, Subbarao K, Fauci A S. Chasing seasonal influenza-the need for a universal influenza vaccine [J]. N Engl J Med, 2018, 378 (1): 7–9.

    [22] Hayden F G, Sugaya N, Hirotsu N, Lee N, de Jong M D, Hurt A C, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A, Baloxavir Marboxil Investigators G. Baloxavir marboxil for uncomplicated influenza in adults and adolescents [J]. N Engl J Med, 2018, 379 (10): 913–923.

    [23] Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses [J]. Antiviral Res, 2018, 153: 85–94.

    [24] Deyde V, Garten R, Sheu T, Smith C, Myrick A, Barnes J, Xu X, Shaw M, Klimov A, Gubareva L. Genomic events underlying the changes in adamantane resistance among influenza A (H3N2) viruses during2006–2008 [J]. Influenza Other Respir Viruses, 2009, 3 (6): 297–314.

    [25] Ison M G. Antivirals and resistance:influenza virus [J]. Curr Opin Virol, 2011, 1 (6): 563–573.

    [26] Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic [J]. J Antimicrob Chemother, 2005, 55Suppl 1: i5–i21.

    [27] Lackenby A, Besselaar T G, Daniels R S, Fry A, Gregory V, Gubareva L V, Huang W, Hurt A C, Leang S K, Lee RTC, Lo J, Lollis L, Maurer-Stroh S, Odagiri T, Pereyaslov D, Takashita E, Wang D, Zhang W, Meijer A. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017 [J]. Antiviral Res, 2018, 157: 38–46.

    [28] Lindstrom S E, Cox N J, Klimov A. Genetic analysis of human H2N2 and early H3N2 influenza viruses, 1957–1972: evidence for genetic divergence and multiple reassortment events [J]. Virology, 2004, 328 (1): 101–119.

    [29] Scholtissek C, Rohde W, Von Hoyningen V, Rott R. On the origin of the human influenza virus subtypes H2N2 and H3N2 [J]. Virology, 1978, 87 (1): 13–20.

    [30] Smith G J, Vijaykrishna D, Bahl J, Lycett S J, Worobey M, Pybus O G, Ma S K, Cheung C L, Raghwani J, Bhatt S, Peiris J S, Guan Y, Rambaut A. Origins and evolutionary genomics of the 2009swine-origin H1N1influenza A epidemic [J]. Nature, 2009, 459 (7250): 1122–1125.

    [31] Shaw A. New technologies for new influenza vaccines [J]. Vaccine, 2012, 30 (33): 4927–4933.

    [32] Erbelding E J, Post D J, Stemmy E J, Roberts P C, Augustine A D, Ferguson S, Paules C I, Graham B S, Fauci A S. A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases [J]. J Infect Dis, 2018, 218 (3): 347–354.

This Article


CN: 11-1865/R

Vol 34, No. 06, Pages 789-792

November 2018


Article Outline